6 results about "Ginkgolide-B" patented technology

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention provides application of bilobalide B in inhibiting cerebral ischemia reperfusion injury caused by ferroptosis, and relates to the field of cerebral ischemia reperfusion injury. According to the application, ginkgolide B inhibits ferroptosis by regulating an Nrf2 / H0-1 pathway so as to improve cerebral ischemia reperfusion injury, regulation of Nrf2 / H0-1 promotes nuclear translocation of Nrf2 and up-regulates expression of a downstream antioxidant gene HO-1 so as to relieve spinal cord injury by inhibiting ferroptosis, and up-regulation of the expression of the downstream antioxidant gene HO-1 is that when cells are stimulated by hypoxia, the expression of the downstream antioxidant gene HO-1 is inhibited so as to inhibit the ischemia reperfusion injury. And the Nrf2 is dissociated from the Keap1 and is translocated to a cell nucleus. The action mechanism of the ginkgolide B for inhibiting the ferroptosis process and improving the CIRI by regulating and controlling an Nrf2 / HO-1 signal channel is explored, and a research strategy of combining bioinformatics prediction and experimental verification is adopted, so that a foundation is laid for deeply analyzing the neuroprotective action mechanism of the ginkgolide B; and a new research thought and a potential target spot are provided for developing a novel ginkgo leaf-related active ingredient medicine.

The present application provides a kind of pharmaceutical composition for vulvar sclerosing lichen and its preparation method, the pharmaceutical composition includes active ingredient and pharmaceutically acceptable vulva local administration adjuvant, active ingredient is made of 0.005-0.02 parts of mometasone furoate, 0.05-0.3 parts of calcineurin inhibitor, 0.5-2 parts of paeoniflorin, 0.8-3 parts of asiaticoside, 0.3-1.5 parts of recombinant collagen, 0.2-1 part of ginkgolide B.The present application is aimed at the core pathogenesis of disease, constructs multi-target whole course of disease synergistic therapy system, can realize anti-inflammatory regulation, anti-fibrosis, basement membrane repair, microcirculation improvement simultaneously, low-dose strong effect, greatly reduce side effect and recurrence rate;Liposome targeted delivery technology is used, the stability of active ingredient is guaranteed, process controllable adaptation industrialization production, and clinical application prospect is wide.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.